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Abstract 
Background: The widespread application of protein-derived bioactive peptides (BAPs) with 
health promoting properties in human nutrition is currently limited. This may be due to the fact 
that several challenges exist in the discovery and identification of BAPs both in vitro and in vivo. 
Scope and approach: To date, most BAP studies have been conducted following a so-called 
“conventional” approach. This is based on the non-targeted release of BAPs in vitro, followed, in 
certain instances, with their subsequent evaluation in vivo. However, more targeted approaches 
have recently been described for the release of specific BAPs in a more predictable and efficient 
manner. These targeted approaches are mostly based on in silico protocols (e.g., peptide cutters, 
molecular docking, quantitative structure activity relationship (QSAR) models) aimed at 
predicting the release and/or the bioactivity of specific peptides. 
Key findings: Targeted approaches have, in certain instances, resulted in the development of 
particularly potent BAPs/hydrolysates and the discovery of novel BAP sequences. In addition, 
significant progress has been made in the identification of short peptides, involving the 
utilisation of multi-stage processes combining various physicochemical, analytical and in silico 
tools. This has allowed identification of novel sequences which are more relevant to human 
health from a bioavailability and stability perspective. BAPs have successfully been detected and 
quantified in human samples (e.g., serum, intestinal contents and urine) using different liquid 
chromatography-mass spectrometric (LC-MS) methodologies. In addition, human dose-response 
studies have allowed determination of their in vivo potency and efficacy, which in turn 
contributes to the development of scientific dossiers for regulatory approval. 
Key words: dietary proteins; bioactive peptides; in silico; bioavailability; short peptides; human 
studies. 
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1  Introduction 1 
Food proteins have been studied widely for their positive contribution to human health. 2 
Subsequent to protein digestion, amino acids are incorporated into proteins within the human 3 
body. In addition, dietary proteins also contain specific peptide sequences, called bioactive 4 
peptides (BAPs). A large number of in vitro studies has demonstrated that these BAPs may 5 
beneficially modulate markers of health (for reviews, see: Bhat, Kumar, & Bhat, 2015; Halim, 6 
Yusof, & Sarbon, 2016; Hernández-Ledesma, García-Nebot, Fernández-Tomé, Amigo, & Recio, 7 
2014; Li-Chan, 2015; Maestri, Marmiroli, & Marmiroli, 2016; Suleria, Gobe, Masci, & Osborne, 8 
2016). In addition, some of these peptides have been evaluated in humans, and positive health 9 
outcomes have been reported in certain instances. To date, most human studies evaluating the 10 
health benefits of dietary BAPs appear to have been carried out with milk and soy protein 11 
hydrolysates or fermentates (for reviews, see: Hsieh et al., 2015; Nongonierma & FitzGerald, 12 
2012a; Nongonierma & FitzGerald, 2015a, 2015b; Udenigwe & Aluko, 2012). 13 
In a global context of increased health-related problems which are notably linked with the 14 
metabolic syndrome, adherence to a healthier diet has been acknowledged as one of the key 15 
components for maintenance of a healthy status in humans (O'Neill & O'Driscoll, 2015). 16 
Consequently, the requirement for high quality dietary proteins has increased significantly due to 17 
consumer demand. Several food processing protein-rich by-products have conventionally been 18 
used for animal nutrition either in their intact or hydrolysed format (Martínez-Alvarez, 19 
Chamorro, & Brenes, 2015). However, there is an increasing interest in valorising these 20 
underutilized protein sources in human nutrition (Lemes et al., 2016). Therefore, a wide range of 21 
dietary proteins originating from animal, plant and algal sources are currently being investigated 22 
for their potential to act as BAP precursors (Udenigwe & Aluko, 2012). Conventionally, food-23 
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grade BAPs have been released from dietary proteins using enzymatic hydrolysis, microbial 24 
fermentation and/or physical processes (e.g., high pressure, sonication, etc.). However, currently 25 
enzymatic hydrolysis and fermentation are the most common means to produce dietary BAPs 26 
(Udenigwe & Aluko, 2012). 27 
BAPs may be included in foods in order to provide additional health benefits to the general 28 
population. Nevertheless, several limitations/challenges have been reported for the development 29 
of BAPs targeted at human nutrition (for reviews, see: Li-Chan, 2015; Nongonierma & 30 
FitzGerald, 2016b). These include limited knowledge of BAP sequences when they are released 31 
within protein hydrolysates, which is particularly related to the high level of compositional 32 
complexity of protein hydrolysates. In addition, poor knowledge of the mode of action of BAPs 33 
currently exists. Finally, there appears to be a limited number of human studies which have 34 
shown a direct relationship between the ingestion of food protein hydrolysates and enhanced 35 
health-related properties (Nongonierma & FitzGerald, 2015b). 36 
Due to uncertainties surrounding the demonstrated efficacy and the mode of action of 37 
BAPs/hydrolysates, their regulatory approval in many countries is extremely difficult. Health 38 
claims are granted to food components by the European Food Safety Authority (EFSA) based on 39 
scientific substantiation while the Food Drug Administration (FDA, USA) and the Ministry of 40 
Health, Labour and Welfare (MHLW, Japan) may grant health claims based on suggested 41 
scientific evidence (Lalor & Wall, 2011). To date, in Europe and the USA it appears that no 42 
protein-derived BAP-based ingredient/food has been granted health claims by EFSA or the FDA. 43 
However, in Japan, the situation is quite different, where a number of BAP-based foods have 44 
been recognised as so-called “food for specified health uses” (FOSHU) by the MHLW (Arai, 45 
Yasuoka, & Abe, 2008; Shimizu & Hettiarachchy, 2012). The negative opinions provided by 46 
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EFSA to regulatory application dossiers for peptide-based ingredients with health promoting 47 
activity have either been due to a lack of full characterisation of the active ingredients or an 48 
inconsistent link between BAP ingestion and the proposed health benefit in the specific target 49 
population (De Noni et al., 2009). Guidelines in relation to health claim dossiers have been made 50 
available by EFSA to assist applicants in the regulatory dossier preparation process (EFSA, 51 
2011). These guidelines have recently been updated (EFSA, 2016). 52 
Over the past number of years, the scientific community and the food ingredient sector have 53 
attempted to close the gap between ongoing BAP research and their application in functional 54 
foods. Significant efforts have been made in the development of more potent dietary protein 55 
hydrolysates, the characterisation of BAP sequences within these hydrolysates, along with 56 
mechanistic and human intervention studies to assess their bioactive properties. To date, the 57 
study of BAPs has been carried out in a rather conventional manner. The workflow describing 58 
the conventional production of dietary protein hydrolysates starts with in vitro generation to 59 
peptide identification followed by in vivo testing of selected hydrolysates (Figure 1). This 60 
conventional approach may be time consuming and inefficient in the discovery and development 61 
of potent bioactive food protein hydrolysates. However, the development of more powerful 62 
computers and software has allowed the use of computational methodologies in the study of 63 
BAPs. More targeted alternative approaches have been developed which are mainly based on the 64 
utilisation of in silico methodologies and/or knowledge of BAPs which have been identified in 65 
humans (for reviews, see: Agyei, Ongkudon, Wei, Chan, & Danquah, 2016; Capriotti, Cavaliere, 66 
Piovesana, Samperi, & Laganà, 2016; Carrasco-Castilla, Hernández-Álvarez, Jiménez-Martínez, 67 
Gutiérrez-López, & Dávila-Ortiz, 2012; Iwaniak, Minkiewicz, Darewicz, Protasiewicz, & 68 
Mogut, 2015; Li-Chan, 2015; Nongonierma & FitzGerald, 2016b; Udenigwe, 2014; Udenigwe & 69 
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Aluko, 2012). In many instances, the alternative approaches have shown promise in the 70 
generation and identification of BAPs with enhanced potency, higher bioavailability and/or of 71 
more relevance to humans. 72 
The aim of this review was to assess the main limitations in the conventional approach to the 73 
discovery and identification of dietary BAPs and to outline alternative strategies to enhance this 74 
process. 75 
2 Conventional approach to study dietary BAPs and its limitations 76 
Conventional approaches for BAP studies have been described in the scientific literature (Agyei 77 
et al., 2016; Capriotti et al., 2016; Carrasco-Castilla et al., 2012; Li-Chan, 2015; Nongonierma & 78 
FitzGerald, 2016b). These approaches involve a stepwise process (Figure 1) which has yielded 79 
the successful identification and evaluation of dietary BAPs. However, several limitations exist 80 
with the conventional approach which are summarised in Figure 1. These will be discussed in 81 
further detail in the following subsections. 82 
2.1 Generation of food protein hydrolysates 83 
The first step of the conventional approach consists in the selection of the protein substrate and 84 
the proteolytic/peptidolytic enzyme preparation for hydrolysate generation. The selection of 85 
protein and enzyme combinations are mainly aided with information from the scientific 86 
literature, knowledge of protein sequences and enzyme specificity (Udenigwe & Aluko, 2012). 87 
In the conventional approach, selection of the protein substrate may be quite empirical (linked to 88 
substrate availability, potential source of BAPs, underutilised protein, cost, etc.). Several 89 
commercially available food-grade enzyme preparations have been described in the development 90 
of protein hydrolysates. Lemes et al. (2016) recently reviewed the main enzyme preparations 91 
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which have been employed for the release of BAPs from food by-products. Generally, the 92 
enzyme preparations used for the development of food protein hydrolysates originate from 93 
animal, microbial or plant sources (Nongonierma & FitzGerald, 2011). Currently, selection of 94 
the enzyme preparation arises from (1) knowledge of the specificity of the main activity therein, 95 
if available, or (2) indications in the literature of its potential to release certain BAPs. 96 
Following selection of the substrate(s) and enzyme preparation(s), the hydrolysis conditions (i.e., 97 
pH, temperature, time, enzyme to substrate (E:S) ratio, total solids, etc.) need to be chosen. 98 
These conditions may influence the release of BAPs as they can modify both substrate 99 
conformation and enzyme activity and therefore the accessibility of specific peptide bonds in 100 
proteins. For instance, it was demonstrated that the protein concentration (0.1-10.0% (w/v)) at 101 
which whey protein isolate (WPI) was hydrolysed by a Bacillus licheniformis protease, modified 102 
the cleavage specificity of certain peptide bonds within -lactoglobulin (-Lg) (Butré, Sforza, 103 
Gruppen, & Wierenga, 2014). Similarly, -Lg peptide bond selectivity for cleavage by a B. 104 
licheniformis protease depended on the pH (7.0-9.0) at which the hydrolysis reaction was 105 
conducted (Butré, Sforza, Wierenga, & Gruppen, 2015). To date, optimisation of the in vitro 106 
generation of food protein hydrolysates appears to have been conducted following modifications 107 
of the hydrolysis parameters one at a time. This approach has some limitations as it can be 108 
relatively time consuming, generating a large number of samples. In addition, it does not allow 109 
an understanding of the contribution of each parameter, nor the interactive effects between them. 110 
Furthermore, the optimum hydrolysis parameters for BAP release are ultimately not likely to be 111 
determined with this empirical approach. For this reason a more comprehensive approach to 112 
BAP generation has been described which involve the use of multifactorial design of 113 
experiments (DOE) and response surface methodologies (RSM) (van der Ven, Gruppen, de Bont, 114 
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& Voragen, 2002). Specific examples of RSM used as an optimisation tool for BAP release will 115 
be described in section 4. 116 
2.2 In vitro bioactivity assessment of hydrolysates 117 
Dietary BAPs have been assessed for their biological potential using a wide range of in vitro 118 
bioassays involving cells grown in culture along with specific chemical or enzymatic reactions. 119 
These bioassays are essentially based on the same protocols as those routinely used in drug 120 
discovery. The different bioassays used for BAP analysis evaluate the extent of chemical 121 
reactions, enzyme inhibition, receptor binding as well as metabolite profiling (for reviews, see: 122 
de Castro & Sato, 2015; Nongonierma & FitzGerald, 2016b). However, several parameters may 123 
influence the bioactivity results. These include the reactant concentration (hydrolysates/peptides 124 
and other test reagents), purity and origin as well as temperature, pH, number of passages of cells 125 
in culture, etc. For example, in enzyme inhibition assays, a large variability in the half maximal 126 
inhibitory concentration (IC50) of BAPs/hydrolysates has been demonstrated when tested at 127 
different E:S ratios in the angiotensin converting enzyme (ACE, EC 3.4.15.1) inhibitory assay 128 
(Murray, Walsh, & FitzGerald, 2004). Furthermore, in the presence of specific peptide substrates 129 
or inhibitors, variability in enzyme activity has been reported which depended on the organism 130 
from which the enzyme originated. This was the case for different bacterial sources of prolyl 131 
endopeptidases (EC 3.4.21.26) (Shan, Marti, Sollid, & Khosla, 2004) and for porcine and human 132 
recombinant dipeptidyl peptidase IV (DPP-IV, EC 3.4.14.5) (Lacroix & Li-Chan, 2015). 133 
Nevertheless, communalities between different research groups performing the same assay are 134 
found. Generally, specific bioassays are conducted with similar positive/negative controls to 135 
allow for the comparison of different test samples. These controls may consist of reference 136 
chemical compounds which may be a pharmaceutical drug (e.g., Captopril for ACE inhibition, 137 
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Sitagliptin for DPP-IV inhibition, Allopurinol for xanthine oxidase (EC 1.2.3.2) inhibition), a 138 
synthetic compound (e.g., Trolox
TM
, butylated hydroxyanisole (BHA), butylated hydroxytoluene 139 
(BHT) for antioxidant assays) or peptides known to positively impact on bioactivity (e.g., Ile-140 
Pro-Pro for ACE inhibition, Ile-Pro-Ile (Diprotin A) for DPP-IV inhibition, Glu-Cys-Gly 141 
(glutathione) or Ala-His (carnosine) for antioxidant properties). In antioxidant assays for 142 
example, it is common practice to express the potency of the BAPs as an equivalent of the 143 
positive control (Trolox). Nevertheless, for most bioassays, this is not the case, making it 144 
challenging to compare data across different studies, due to the large variability in the setup of 145 
the in vitro bioassays. 146 
In many research areas, standard methodologies have been established to provide a greater level 147 
of confidence and cross validation in the characterisation and evaluation of test compounds. This 148 
is the case for instance with methods related to analysis of food composition which have been 149 
certified by international scientific associations such as the International Organisation for 150 
Standardisation (ISO), the International Dairy Federation (IDF) or the Association of Official 151 
Analytical Chemists (AOAC). To date, such standardised methods do not seem to be available 152 
for the bioassays used in the evaluation of BAPs. Standardisation of bioassay protocols is 153 
ultimately required to facilitate the study of BAPs and increase the level of understanding of the 154 
compounds which are likely to be highly potent. 155 
There is currently a relatively low level of confidence regarding the appropriateness of different 156 
in vitro bioassays for assessment of relevant markers to specific disease/health conditions. In 157 
most cases, the aetiology of specific diseases is quite complex and therefore involves several 158 
mechanisms of action. Therefore, using a single bioassay to identify a disease reducing agent is 159 
questionable as most in vitro bioassays are quite specific. For this reason, recent publications are 160 
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beginning to combine different bioassays to study food protein hydrolysates/BAPs in order to 161 
target a wider range of biological markers linked with a specific disease/health condition (Girgih 162 
et al., 2014; Lacroix, Meng, Cheung, & Li-Chan, 2016; Majumder et al., 2015; Nongonierma & 163 
FitzGerald, 2013a; Yousr & Howell, 2015). 164 
2.3 Enrichment and fractionation of BAPs 165 
Bioactivity determination is used as a means to rank different hydrolysates in terms of their 166 
biological potency. The peptide composition of many hydrolysates may be highly complex 167 
(Capriotti et al., 2016). Therefore, this presents a difficulty in understanding which peptides 168 
within complex mixtures are exerting a specific bioactivity. For this reason, fractionation and/or 169 
peptide enrichment techniques may be employed to reduce the compositional complexity of 170 
hydrolysates and subsequently allow identification of those peptides contributing to the bioactive 171 
properties. Peptides may be further fractionated with techniques based on different 172 
physicochemical properties such as molecular mass, hydrophobicity or charge (for reviews, see: 173 
Dallas et al., 2015; Lemes et al., 2016; Nongonierma, O’Keeffe, & FitzGerald, 2016b; Panchaud, 174 
Affolter, & Kussmann, 2012). 175 
A bioactivity-driven fractionation approach is often used in order to determine that 176 
enrichment/purification of the BAPs has occurred (Carrasco-Castilla et al., 2012). Fractionation 177 
of BAPs is a time consuming process and often requires combination of several techniques to 178 
bring about separation of BAPs from other inactive peptides within complex hydrolysates. 179 
Generally, peptide fractionation is accompanied by an increased activity in selected fractions 180 
compared to the starting hydrolysate. In addition, modifications of peptide-peptide 181 
physicochemical (i.e., hydrophobic and electrostatic) interactions may prevail in complex 182 
peptide mixtures which may in turn hinder overall bioactivity (Groleau, Morin, Gauthier, & 183 
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Pouliot, 2003; Mercier, Gauthier, & Fliss, 2004). In certain instances, a reduction in peptide 184 
compositional complexity following fractionation may be accompanied with a loss/reduction in 185 
bioactive properties. In fact, certain hydrolysates contain peptide sequences which concomitantly 186 
contribute to the overall bioactivity as they are able to interact in various ways, e.g., in an 187 
additive, synergistic or antagonistic manner (Nongonierma & FitzGerald, 2015c; Schanbacher, 188 
Talhouk, Murray, Gherman, & Willett, 1998). 189 
2.4 Peptide identification 190 
When a highly bioactive fraction has been obtained, it can be further characterised by 191 
identification of the peptide sequences therein. This generally involves the utilisation of front end 192 
separative techniques (e.g., liquid chromatography (LC) or capillary electrophoresis (CE)) 193 
coupled with mass spectrometry (MS) (Dallas et al., 2015; Panchaud et al., 2012). As fractions 194 
are less complex than the starting hydrolysate from a peptide composition point of view, 195 
conducting the MS characterisation on the fractions is a means to narrow down the peptide 196 
candidates responsible for specific bioactive properties (Panchaud et al., 2012). Confirmatory 197 
studies may then be carried out with selected sequences using synthetic peptides which are 198 
assessed in vitro for their bioactive properties. 199 
To date, most MS systems are able to accurately detect peptides  5 amino acid residues in 200 
length. In contrast, shorter peptides (2-4 amino acids) have been underreported, to date, in the 201 
literature. This is possibly due to analytical limitations. The under or over fragmentation of short 202 
peptides in tandem MS has made their detection complicated and challenging (Dallas et al., 203 
2015; Lahrichi, Affolter, Zolezzi, & Panchaud, 2013). However, the bioavailability and stability 204 
of short peptides is thought to be higher compared to larger peptides which are more likely to be 205 
further processed during gastrointestinal digestion, intestinal permeation and in the circulation 206 
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(Foltz, Van Buren, Klaffke, & Duchateau, 2009; Webb, Matthews, & DiRienzo, 1992). The 207 
identification of short peptides is therefore crucial for research involving dietary BAPs as these 208 
sequences are likely to be relevant to human health. 209 
2.5 In vivo studies 210 
To date, there does not appear, in many instances, to be a direct link between the occurrence of 211 
dietary peptides in humans and their presupposed health benefits (for reviews: see Miner-212 
Williams, Stevens, & Moughan, 2014; Nongonierma & FitzGerald, 2015b). Additional in vitro 213 
studies may need to be performed in order to enhance the relevance of in vitro findings to human 214 
health. These include in vitro simulated gastro-intestinal digestion of the hydrolysates, 215 
assessment of their cytotoxicity, or peptide permeation through cell culture-based intestinal layer 216 
models (De Noni, Stuknytė, & Cattaneo, 2015; Egger et al., 2016; Mat, Le Feunteun, Michon, & 217 
Souchon, 2016; Minekus et al., 2014; Picariello, Ferranti, & Addeo, 2016; Picariello et al., 2010; 218 
Picariello et al., 2013a; Stuknytė, Cattaneo, Masotti, & De Noni, 2015; Walsh et al., 2004). 219 
Based on the outcomes of all the above experiments, in vivo studies may initially be performed 220 
in animal models (Fernández-Musoles et al., 2014; Gaudel et al., 2013; Mukhopadhya et al., 221 
2015; Yamada et al., 2015; Zhang, Chen, Jiang, Yin, & Zhang, 2016a). Different animal models 222 
of disease are available for testing biological compounds (for reviews, see: Aydin et al., 2014; 223 
Nelson & Reusch, 2014). Animal studies are often used before human studies for mechanistic 224 
purposes and to evaluate possible toxic effects in vivo. Several hydrolysates have also been 225 
directly evaluated in humans notably for their antihypertensive, antidiabetic and mineral binding 226 
properties (for reviews, see: Boutrou, Henry, & Sanchez-Rivera, 2015; Fekete, Givens, & 227 
Lovegrove, 2013; Nongonierma & FitzGerald, 2012a, 2015b). In vivo trials are generally 228 
performed at the last stage of the study, due to their high cost, time requirement and for ethical 229 
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reasons (Foltz, van der Pijl, & Duchateau, 2010). In vivo studies ultimately serve to confirm the 230 
bioactive potential of hydrolysates. While positive outcomes have been reported in several 231 
human studies, conflicting results have been found, sometimes making it difficult to understand 232 
the beneficial role of BAPs in human health. This conflicting information may arise from the 233 
poor bioavailability/stability of the BAPs as well as human interindividual variability (genetic, 234 
phenotypic, non-responders, gut microbiota, health status, etc.) (Nongonierma & FitzGerald, 235 
2015b). 236 
Promising studies based on LC-MS characterisation of human fluids, both in the gastrointestinal 237 
tract (Boutrou et al., 2013) and in the circulation (Foltz et al., 2007; Kaiser et al., 2016; Morifuji 238 
et al., 2010), have demonstrated that certain BAPs were present within the human body 239 
following intake of intact or hydrolysed proteins. However, further quantitative studies are 240 
needed to verify that these BAPs are present in sufficient quantities to induce their biological 241 
effects. 242 
Overall, the conventional approach currently in use for dietary protein hydrolysate evaluation is a 243 
time-consuming and complicated process which may not guarantee the identification of specific 244 
BAPs (Capriotti et al., 2016). For these reasons, many research groups have attempted to 245 
improve the workflow used both during BAP generation and identification. The following 246 
sections outline examples of methodological approaches alternative to the conventional strategy 247 
which have been described in the literature to improve the release, identification and in vivo 248 
validation of BAPs. 249 
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3 Targeted approaches for the discovery and identification of BAPs 250 
The components of an alternative more targeted approach are outlined in Figure 1. These 251 
approaches may help to improve the generation, discovery and validation of BAPs. They 252 
comprise the utilisation of different in silico tools at the peptide generation, identification and 253 
validation stages. As already outlined, in silico tools are computational tools which are based on 254 
the utilisation of computers and various software (Iwaniak et al., 2015). The broad application of 255 
in silico methodologies to study peptides has been facilitated by the large number of freely 256 
available software and peptide databases. One commonly used peptide repository for in silico 257 
analysis of BAPs is the BIOPEP database (Minkiewicz, Dziuba, Iwaniak, Dziuba, & Darewicz, 258 
2008). Other BAP databases and software have also been reported in the literature, which may 259 
aid in the design of novel and more potent peptides (for review, see: Iwaniak et al., 2015; 260 
Nongonierma & FitzGerald, 2016b). 261 
Numerous enzyme preparations and dietary proteins have been described for the generation of 262 
BAPs. Therefore, a large number of enzymesubstrate combinations may be employed to 263 
generate protein hydrolysates. The predicted release of BAPs from food proteins has been 264 
employed in order to develop more targeted approaches (Capriotti et al., 2016). In silico 265 
approaches may be used to guide researchers/industry in the selection of the most promising 266 
protein substrates.  267 
A rapid means to interrogate the dietary proteome is to systematically search for known BAP 268 
sequences within a dataset of protein sequences (Dziuba, Iwaniak, & Minkiewicz, 2003; Dziuba 269 
& Darewicz, 2007). In silico analyses have been conducted on dietary proteins originating from 270 
plant (Chang & Alli, 2012; Cheung, Nakayama, Hsu, Samaranayaka, & Li-Chan, 2009; 271 
Udenigwe, 2016; Vecchi & Añón, 2009), milk (Dziuba & Dziuba, 2014; Tulipano, Faggi, 272 
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Nardone, Cocchi, & Caroli, 2015), fish (Darewicz, Borawska, & Pliszka, 2016; Huang, Lin, & 273 
Chang, 2015), meat (Keska & Stadnik, 2016; Lafarga, O’Connor, & Hayes, 2015) and insects 274 
(Vercruysse et al., 2009) to study their potential to act as substrates for the generation of BAPs. 275 
This approach has also been specifically described for the identification of staple food proteins 276 
which may be useful for the generation of ACE (Gu, Majumder, & Wu, 2011b; Vermeirssen, van 277 
der Bent, Van Camp, van Amerongen, & Verstraete, 2004) and DPP-IV (Lacroix & Li-Chan, 278 
2012; Nongonierma & FitzGerald, 2014) inhibitory peptides. Different methodologies have been 279 
employed to rank proteins for their bioactive potential (Table 1). Protein ranking based on the 280 
frequency of occurrence of BAPs (A) within their sequence (Table 1) has been described by 281 
Dziuba et al. (2003). 282 
The main limitations of ranking proteins based on this approach are that the frequency of BAP 283 
occurrence may incorporate overlapping peptide sequences and that bioactive potency is not 284 
taken into account. To address these issues, different indexes incorporating peptide potency have 285 
been proposed in the literature. The potential bioactivity index of food proteins was first 286 
introduced by Dziuba et al. (2003), which incorporated parameters such as the half maximal 287 
effective concentration (EC50) of the peptides identified within protein sequences (Table 1). 288 
Vermeirssen et al. (2004) employed a scoring approach taking into account the ACE IC50 value 289 
and molecular mass of the protein (pea and milk proteins) in their in silico study (Table 1). They 290 
developed two scoring systems to take into account the presence of overlapping peptide 291 
sequences within protein sequences, by prioritising the most potent peptides (score 1) and 292 
subsequently prioritising the shortest and most potent peptides (score 2). An in silico model was 293 
developed by Nongonierma and FitzGerald (2014) to take account of the fact that each amino 294 
acid residue can only contribute to one peptide sequence at a time within a given region of the 295 
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protein containing overlapping BAP sequences. In this model, only the most potent DPP-IV 296 
inhibitory peptide was considered (regardless of its size). Furthermore, a potency index was 297 
developed incorporating peptide potency (i.e., IC50) and molecular mass of the protein (Table 1). 298 
In another study on milk proteins, Tulipano et al. (2015) also incorporated a peptide DPP-IV IC50 299 
value in their in silico analysis. Peptide candidates identified within -lactalbumin (-La) and -300 
Lg were classified into four groups (i.e., DPP-IV IC50 < 100, 100-200, 200-500 and 500-1600 301 
µM) based on the structural similarity of their N-terminal dipeptide sequence to previously 302 
identified DPP-IV inhibitory peptides. In both models developed by Vermeirssen et al. (2004) 303 
and Nongonierma and FitzGerald (2014), discrepancies were found between BAP occurrence 304 
and potential predicted bioactivity of proteins. For this reason, it was concluded that the number 305 
of BAPs was not a good predictor of the bioactivity potential of proteins (Vermeirssen et al., 306 
2004), suggesting that it may be more accurate to routinely incorporate BAP potency in in silico 307 
predictions. 308 
One of the most common in silico tools consists in the use of peptide cutter programmes. These 309 
software are used to predict amino acid/peptide release from specific protein substrates based on 310 
knowledge of cleavage specificity of specific enzyme activities. Peptide cutters have been 311 
employed to predict starting protein substrate(s) or enzyme(s) which should release previously 312 
reported BAPs (Chang & Alli, 2012; Cheung et al., 2009; Fu, Wu, Zhu, & Xiao, 2015; 313 
Majumder & Wu, 2010; Minkiewicz, Dziuba, & Michalska, 2011; Nongonierma, Le Maux, 314 
Hamayon, & FitzGerald, 2016a; Tulipano et al., 2015; Udenigwe, Gong, & Wu, 2013; 315 
Vermeirssen et al., 2004). Peptide cutter outputs may be employed to determine the frequency of 316 
BAP release from proteins by a given enzyme activity (AE, Table 1) (Minkiewicz et al., 2011). 317 
Specific features of BAPs may be incorporated in the model when the bioactivity of the peptides 318 
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is not available in the literature. For instance, peptides predicted to be released from bovine 319 
caseins, having an N-terminal Xaa-Pro/Ala (with Xaa an amino acid) were specifically taken into 320 
account to calculate a frequency of occurrence for DPP-IV inhibitory peptides (Hsieh et al., 321 
2016). Another strategy has been described to overcome the variability seen in the biological 322 
data as well as the availability of specific peptide sequences within BAP databases. For instance, 323 
Pripp (2005) combined C-terminal cleavage post each of the 20 conventional amino acids in milk 324 
protein sequences, followed by in silico gastrointestinal digestion of the resulting peptides 325 
predicted to be released and estimation of their ACE IC50 values using quantitative structure 326 
activity relationship (QSAR) modelling. They developed a model to predict the ACE IC50 of 327 
protein hydrolysates which was based on in silico prediction of peptide release and their 328 
predicted ACE IC50 value (Table 1). 329 
In many instances, the in silico enzymatic digestion of proteins was confirmed by the in vitro 330 
generation of hydrolysates. This was the case for pea, egg and bovine whey proteins (Majumder 331 
& Wu, 2010; Nongonierma et al., 2016a; Tulipano et al., 2015; Vermeirssen et al., 2004). In 332 
several studies, validation of the in silico prediction was demonstrated at a macromolecular level 333 
with the in vitro generation of bioactive protein hydrolysates. For example, the ability of 334 
thermolysin to produce more potent ACE inhibitory oat protein hydrolysates than subtilisin (EC 335 
3.4.21.62) or pepsin (EC 3.4.4.1) was validated by the in vitro evaluation of the corresponding 336 
hydrolysates (Cheung et al., 2009). Similarly, confirmation of a higher ACE inhibitory potency 337 
following gastrointestinal digestion of whey proteins compared to pea proteins has been 338 
demonstrated (Vermeirssen et al., 2004). In vitro gastrointestinal digests of -Lg yielded higher 339 
DPP-IV inhibition than those of -La as predicted in silico (Tulipano et al., 2015). A higher 340 
DPP-IV inhibition of tryptic (EC 3.4.21.4) caprine compared to tryptic bovine casein 341 
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hydrolysates was found after 3 h enzymatic hydrolysis as per in silico prediction (Zhang et al., 342 
2016b). 343 
Studies based on in silico predictions for the release of potent BAPs have proved very useful as a 344 
decision tool for the selection of both protein substrates and enzyme activities. However, at a 345 
molecular level, a direct translation between predicted and in vitro peptide release has not been 346 
systematically verified, as demonstrated in a number of studies. For example, Nongonierma et al. 347 
(2016a) showed that 60% of the peptides which were predicted to be released following 348 
digestion of -La with pancreatic elastase (EC 3.4.21.36) were actually identifiable by LC-349 
MS/MS. Similar results have been reported with peptic digests of ovotransferrin, where only the 350 
precursors of the target ACE inhibitory peptides predicted to be released in silico could be 351 
identified by LC-MS/MS within the hydrolysate (Majumder & Wu, 2010). Recently, differences 352 
in ACE inhibitory peptides predicted to be released in silico and those detected by LC-MS/MS in 353 
a papain digest of bovine collagen were also reported (Fu et al., 2016). Similarly, potato proteins 354 
were cleaved differently by pepsin in vitro compared to the in silico prediction, generally 355 
resulting in less peptide bonds cleaved in vitro (Rajendran, Mason, & Udenigwe, 2016). Variable 356 
results between in vitro and in silico predictions have been explained by the inability of peptide 357 
cutters to accurately predict peptide release from globular proteins (e.g., -La and 358 
ovotransferrin). In addition, peptide cutters assume that all cleavable peptide bonds would be 359 
accessible to the enzyme and be readily hydrolysed. The purity of the enzyme activity employed 360 
to generate hydrolysates may also affect peptide release in vitro. Furthermore, as already 361 
outlined, cleavage of peptide bonds during protein hydrolysis is dependant of their accessibility 362 
as well as the enzyme activity which is dictated by the experimental hydrolysis conditions (Butré 363 
et al., 2014; Butré et al., 2015; Kalyankar, Zhu, O’Cuinn, & FitzGerald, 2013). Following 364 
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protein denaturation, which may be caused by aggregation during heat-treatment (Dupont et al., 365 
2010; Rahaman, Vasiljevic, & Ramchandran, 2017; Rinaldi, Gauthier, Britten, & Turgeon, 2014; 366 
Wada & Lönnerdal, 2014), enzymatic cross-linking (Havenaar et al., 2013; Monogioudi et al., 367 
2011), glycation (Bouhallab, Morgan, Henry, Mollé, & Léonil, 1999; Cattaneo, Stuknytė, 368 
Masotti, & De Noni, 2017; Pinto et al., 2014) or interfacial interactions (Maldonado-Valderrama, 369 
Wilde, Mulholland, & Morris, 2012), peptide bond accessibility and cleavage during hydrolytic 370 
reactions may be modified, which may subsequently impact on bioactivity. Finally, the role of 371 
post-translational modifications (PTMs) on peptide release and bioactivity is still not fully 372 
understood. PTMs may occur during processing and storage. As they are not taken into account 373 
in in silico digestion of proteins, there is a need to determine PTMs to fully characterise the 374 
peptides within protein hydrolysates (Rajendran et al., 2016). 375 
4 Optimisation of BAP release during enzymatic hydrolysis 376 
Many commercially available food-grade enzyme preparations are crude extracts and contain 377 
several activities which have not been fully characterised. Therefore, the hydrolytic specificity of 378 
several of these enzyme preparations is essentially unknown (Li-Chan, 2015). Conventionally, 379 
optimisation of BAP release during protein hydrolysis reactions generally appears to be 380 
conducted by modification of hydrolysis conditions one at a time. During hydrolysis, various 381 
parameters may affect enzyme activity and therefore the release of BAPs. Because BAP potency 382 
has been generally reported to be relatively low in comparison to drug compounds, the 383 
development of potent hydrolysates is of significant interest. More potent hydrolysates may be 384 
formulated at a lower dosage in food products while still inducing a significant biological effect. 385 
Therefore, several studies have attempted to improve the bioactive potency of hydrolysates by 386 
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carefully selecting the substrate or enzyme preparation or by optimising the hydrolysis 387 
conditions. 388 
Selection of the starting substrate and the enzyme may be aided by the use of peptide cutters, as 389 
already outlined. The optimisation of hydrolysis parameters has been mainly based on the 390 
utilisation of multifactorial DOE combined with RSM. A number of studies using these 391 
approaches have allowed the systematic evaluation of the contribution of various hydrolysis 392 
parameters (i.e., temperature, time, E:S ratio, pH, etc.) to the release of BAPs during enzymatic 393 
hydrolysis of dietary proteins (Abedin et al., 2015; Cheung et al., 2009; del Mar Contreras, 394 
Hernández-Ledesma, Amigo, Martín-Álvarez, & Recio, 2011; Naik, Mann, Bajaj, Sangwan, & 395 
Sharma, 2013; Nikolaev et al., 2016; Nongonierma, Le Maux, Esteveny, & FitzGerald, 2017; 396 
Quirós, Hernández-Ledesma, Ramos, Martín-Álvarez, & Recio, 2012; van der Ven et al., 2002). 397 
Other advantages of hydrolysing food proteins using DOE approaches include a significant 398 
reduction in the number of experiments required while providing the ability to study interactive 399 
effects between hydrolytic parameters. Predictive models linking hydrolysis parameters to 400 
bioactivity can be developed using DOEs. These models can subsequently be used to build RSM 401 
profiles and allow determination of the optimum parameters for the generation of protein 402 
hydrolysates having enhanced bioactive potency (Abedin et al., 2015; Naik et al., 2013). In 403 
general, a good agreement between the predicted and the experimentally determined bioactivity 404 
has been reported. 405 
To date, most DOE-based studies have evaluated the bioactivity of the whole hydrolysate. 406 
Therefore, the contribution of its individual constituents is unknown. An interesting study has 407 
described the application of DOE (using as variables the enzyme preparation (Corolase PP and 408 
Peptidase 433P) and hydrolysis duration) and RSM for optimisation of the release of a bovine 409 
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casein-derived ACE inhibitory peptide (His-Leu-Pro-Leu-Pro) during enzymatic hydrolysis 410 
(Quirós et al., 2012). In this study, it was reported that within the experimental design, a higher 411 
amount of peptide would be released from caseinate using Corolase PP for an hydrolysis 412 
duration of 24 h. 413 
5 Developing strategies for the identification of peptides in complex mixtures 414 
with a focus on short peptides 415 
Peptide sequence identification has conventionally been carried out by Edman degradation or 416 
enzyme-linked immunoassay (ELISA) and these techniques are still being reported for the 417 
identification of specific peptides (Chabance et al., 1995; Chabance et al., 1998; Ledoux et 418 
al., 1999; Meisel et al., 2003). These methodologies, are however quite complex, as they 419 
generally necessitate significant fractionation work prior to peptide identification. The difficulty 420 
of isolating specific peptides from hydrolysates arises from the fact that hundreds of peptides 421 
may be present in any given hydrolysate. Because some peptides may have very similar 422 
physicochemical properties (mass, hydrophobicity, charge, solubility, etc.), they may be very 423 
difficult to separate from each other. More recently, with increased accuracy of MS analysers 424 
and the development of various bioinformatic tools, the detection of peptides has become less 425 
challenging and numerous peptide sequences may be detected simultaneously (Capriotti et al., 426 
2016; Dallas et al., 2015; Panchaud et al., 2012; Sánchez-Rivera, Martínez-Maqueda, 427 
Cruz-Huerta, Miralles, & Recio, 2014b). Nowadays, unfractionated hydrolysates are routinely 428 
characterised by LC-MS/MS, allowing assessment of gross peptide composition. Fractionation 429 
prior to MS characterisation has been employed to help in the determination of the BAPs present 430 
within dietary hydrolysates (Capriotti et al., 2016). The application of fractionation methods may 431 
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result in enrichment in specific peptide sequences, allowing, in certain instances, easier detection 432 
of the BAPs. 433 
The detection of short peptides ( 4 amino acids) within food protein hydrolysates appears to 434 
have been underreported in the area of dietary BAPs (Lahrichi et al., 2013). This may be because 435 
analytical issues are encountered in the detection of short peptides. These issues are linked with 436 
poor UV absorption and the difficulty to obtain meaningful fragmentation during MS analysis. In 437 
addition, short peptides display a low structural diversity which increases the probability of 438 
detecting isobaric fragments within the same sample or samples generated from different protein 439 
substrates, making searches against protein databases and the subsequent peptide identification 440 
quite complicated. 441 
To date, there appears to be a low level of confidence regarding the identification of these short 442 
sequences within dietary hydrolysates. This may be the reason why only a few studies have 443 
attempted to analyse short peptides in complex matrices. However, the combination of different 444 
fractionation approaches, derivatisation methods, front end analytical separation, in silico tools 445 
and altered MS settings has proved beneficial in the identification of short peptide sequences 446 
within complex mixtures (Figure 2). Studies which have successfully identified short peptides 447 
within complex mixtures (model solutions, hydrolysates/fermentates and biological samples) are 448 
summarised in Table 2. It is evident from the literature that short peptide identification requires a 449 
number approaches which are based on their (1) selective fractionation/isolation, (2) 450 
derivatisation, (3) LC separation, (4) retention time prediction and (5) enhanced MS detection 451 
(Figure 2) 452 
The selective isolation of short peptides has been employed on several occasions to separate 453 
them from other materials which are present in the sample and which may hinder their detection 454 
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(i.e., larger peptides, proteins and non proteinaceous materials). Membrane separation such as 455 
ultrafiltration (Eisele, Stressler, Kranz, & Fischer, 2012; Pampanin et al., 2012; Schlichtherle-456 
Cerny, Affolter, & Cerny, 2003) and nanofiltration (Le Maux, Nongonierma, & FitzGerald, 457 
2015a) or adsorbent-based fractionation (Gu, Li, Liu, Yi, & Cai, 2011a; Le Maux et al., 2015a; 458 
Sánchez-Rivera et al., 2014a) may be used to specifically separate short peptides from complex 459 
samples prior to analysis.  460 
Following sample preparation, precolumn derivatisation has been employed to improve the 461 
detection and identification of amino acids and short peptides. Different tagging reagents such as 462 
phenyl isothiocyanate (PITC), naphthalene-2,3-dialdehyde (NDA) or dabsyl chloride have been 463 
reported in this instance (Eisele et al., 2012; Matsui et al., 2002; Shigemura et al., 2011; 464 
Stressler, Eisele, & Fischer, 2013; Sugihara, Inoue, Kuwamori, & Taniguchi, 2012). 465 
Other improvements which may be employed during LC separations consist in the combination 466 
of several separation modes, e.g., reverse-phase (RP), hydrophilic interaction liquid 467 
chromatography (HILIC) and CE (Harscoat-Schiavo et al., 2012; Le Maux, Nongonierma, 468 
Murray, Kelly, & FitzGerald, 2015b; van Platerink, Janssen, & Haverkamp, 2008). As separation 469 
of peptides using these different analytical tools is based on their physicochemical properties 470 
(i.e., hydrophobicity, hydrophilicity and molecular mass), the information gained during these 471 
different analytical methods can be combined to increase the confidence in peptide identification. 472 
This may be particularly relevant with isobaric peptides or peptides with similar hydrophobicity 473 
or hydrophilicity. It may therefore be important to optimise the LC separative method in order to 474 
avoid the potential for co-eluting peptides and facilitate their subsequent MS detection. 475 
Modifications (i.e., HILIC, RP, CE separation modes) of front end separation methodologies 476 
have been described in several instances to improve the analytical separation of short peptides, 477 
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which generally involve the utilisation of relatively long duration LC-gradients (Lahrichi et al., 478 
2013; Le Maux et al., 2015a). 479 
During MS detection, different optimisation steps have been described to analyse short peptides. 480 
These may be classified in two groups including alterations which are performed pre or post MS 481 
analysis. Before MS analysis, different analyser settings may be altered. One common means is 482 
the selective monitoring of ions from known peptide sequences. Using LC-MS/MS, Morifuji, 483 
Koga, Kawanaka, and Higuchi (2009) reported the identification of seven branched-chain amino 484 
acid (BCAA)-containing dipeptides (Ile-Val, Leu-Val, Val-Leu, Ile-Ile, Leu-Ile, Ile-Leu and 485 
Leu-Leu) within a whey protein hydrolysate. This was achieved employing a multiple reaction 486 
monitoring (MRM) approach based on the detection of specific fragment (i.e., diagnostic) ions 487 
arising from these dipeptides. This methodology also allowed quantification of the seven 488 
peptides (with amounts ranging between 0.03 and 3.69 mg for Ile-Ile and Ile-Leu, respectively) 489 
within a whey protein hydrolysate. Similarly, several hydroxyproline (Hyp) containing di- and 490 
tripeptides were quantified in plasma of humans following the consumption of fish scale gelatin 491 
hydrolysates (Ichikawa et al., 2010; Shigemura et al., 2011; Taga, Kusubata, Ogawa-Goto, & 492 
Hattori, 2014) or porcine skin gelatin hydrolysates (Sugihara et al., 2012) using an MRM 493 
approach. In another study, the use of peptide retention time during LC separation, MRM and 494 
variation in the collision energy has been described for the analysis of the 117 di- and tripeptides 495 
representing all possible combinations of Val, Leu and Ile (Lahrichi et al., 2013). Based on the 496 
fragmentation pattern of short peptides, this approach allowed the ability to distinguish isobaric 497 
peptides containing BCAAs (Leu and Ile), which are generally very difficult to identify due to 498 
their identical mass and similar structure (Kaiser et al., 2016). Other studies based on the 499 
monitoring of specific fragments using selected ion monitoring (SIM) and pseudoselected 500 
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reaction monitoring (SRM) (Eisele et al., 2012; Sánchez-Rivera et al., 2014a; Stressler et al., 501 
2013) have proved successful in allowing short peptide identification in complex mixtures (Table 502 
2). Ion monitoring approaches have yielded quite promising results. However, they necessitate 503 
previous knowledge of the target peptides in order to determine the specific fragments of interest 504 
to be monitored. Alterations of the collision energy and transfer time have also proved beneficial 505 
for the fragmentation and subsequent detection of short peptides within milk protein hydrolysates 506 
(Chen et al., 2015; Kaiser et al., 2016; Lahrichi et al., 2013; Morifuji et al., 2009; O’Keeffe & 507 
FitzGerald, 2015). 508 
To date, very few studies have used matrix-assisted laser desorption ionisation (MALDI) 509 
analysers to study short peptides. This has been mainly linked with the relatively high signal to 510 
noise ratio (S/N) seen with short peptides in MALDI. Hong, Tanaka, Yoshii, Mine, and Matsui 511 
(2013) have described a modified MALDI-based method for the identification of short peptides. 512 
Visualisation of dipeptides (Gly-Sar and Val-Tyr) absorbed on rat intestinal membrane has been 513 
reported with a methodology involving phytic acid-aided MALDI-imaging mass spectrometry 514 
(IMS). The role of phytic acid was to interact with salts (e.g., Na
+ 
and K
+
), thereby reducing the 515 
formation of Na- or K-peptide adducts, which are known to increase the S/N ratio and interfere 516 
with short peptide detection. This novel approach has allowed the determination of dipeptide 517 
permeation though intestinal epithelium as well as their stability (Hong et al., 2013). 518 
Metabolites present the same challenges as short peptides in terms of the difficulties associated 519 
with their MS identification. Therefore, MS analysers developed for metabolites detection may 520 
be employed for the study of short peptides. Studies describing the successful identification of 521 
short peptides using ion mobility spectrometry are found in the literature. Ion mobility 522 
spectrometry allows separation of peptides based on both their m/z and mobility (drift time) in 523 
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the MS analyser. Therefore, ion mobility spectrometry is suited for the detection of isobaric 524 
peptides or peptides presenting similar masses. The use of ion mobility spectrometry in the 525 
discrimination of isobaric dipeptides (Gly-Ala/Ala-Gly and Gly-Ser/Ser-Gly (Blagojevic, 526 
Chramow, Schneider, Covey, & Bohme, 2011)), tripeptides (Tyr-Gly-Trp, Trp-Gly-Tyr and Tyr-527 
Trp-Gly (Pollard et al., 2011)) or isotopomer dipeptides (Kaszycki, Bowman, & Shvartsburg, 528 
2016) has been reported. While it may facilitate the detection of short peptides within complex 529 
mixtures, applications of ion mobility spectrometry to the study of BAPs appear to be rare. 530 
The identification of peptides within complex mixtures may be facilitated by various in silico 531 
approaches. Peptidomic methodologies which are currently used for studying BAPs have been 532 
recently reviewed (Dallas et al., 2015; Iwaniak et al., 2015). In silico methods are very useful for 533 
the study of short peptide sequences. As the quality of peptide fragments may not always be 534 
sufficient to identify the amino acid sequence, different in silico tools have been employed. MS 535 
data analysis is based on different algorithms, software and databases which allow processing of 536 
large amounts of data in an automated and comprehensive manner. These software may be 537 
provided with the MS instrument or by independent suppliers. The use of BAP databases is also 538 
very helpful in the identification of peptides with previously reported bioactivities, 539 
truncated/precursor peptide sequences or sequences presenting features of BAPs (Iwaniak et al., 540 
2015; Nongonierma & FitzGerald, 2016c). In addition to automated searches, peptide retention 541 
time models during LC separation have allowed the identification of short peptide sequences 542 
within complex mixtures (Harscoat-Schiavo et al., 2012; Le Maux et al., 2015a; Le Maux et al., 543 
2015b). A limited number of studies have also described how computational methods, such as 544 
QSAR, could be used to predict the bioactivity of peptides identified in complex samples and 545 
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achieve a more targeted identification of BAP sequences identified by LC-MS (Majumder & 546 
Wu, 2009; Sagardia, Iloro, Elortza, & Bald, 2013). 547 
Overall, a majority of the studies which have reported on the identification of short peptides in 548 
complex mixtures appear to have combined different approaches to validate their analysis. Multi-549 
stage processes have been employed combining the utilisation of (1) accurate mass 550 
determination, (2) possible peptide sequences matching this mass, (3) occurrence of these 551 
peptides in selected protein sequences combined with de novo searches, (4) retention time 552 
validation, (5) good quality MS/MS spectra and (6) confirmatory studies with synthetic peptides 553 
(Figure 2). Utilisation of these sequential approaches have allowed a narrowing down of peptide 554 
candidates within complex samples which has, in several instances, led to the identification of 555 
short peptides. 556 
6 Understanding interactive effects between BAPs as well as matrix effects 557 
As already mentioned, a large number of peptide sequences may be found within food protein 558 
hydrolysates. These peptides may interact to decrease or increase the bioactive properties of the 559 
hydrolysate. For this reason it is important to consider the potential for interactive effects 560 
between peptides. While scientists have often highlighted the possibility that peptides in a 561 
mixture might interact, modifying the bioactive properties, very few studies have actually 562 
demonstrated which mechanisms of action were involved. 563 
An isobole approach has been described, showing in vitro additive or antagonistic effects 564 
between binary mixtures of DPP-IV inhibitory peptides (Nongonierma & FitzGerald, 2015c). 565 
The identification of peptide sequences which are able to interact in a synergistic manner to 566 
increase the bioactive properties of hydrolysates is of interest. Peptide mixtures with synergistic 567 
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effects may allow the formulation of more potent samples. With this in mind, mixtures of other 568 
components (foods, lipid-based carriers or drugs) with dietary hydrolysates have shown 569 
promising results in increasing the overall bioactive properties both in vitro and in vivo. The 570 
concomitant administration of the ACE inhibitory lactotripeptides (LTPs - Ile-Pro-Pro, Leu-Pro-571 
Pro and Val-Pro-Pro) with foods (different meals having various protein, carbohydrate, fat and 572 
fiber contents) have resulted in increased bioavailability in pigs. This has been attributed to the 573 
potential modification of the kinetics of digestion and gut metabolism in the presence of foods 574 
(Ten Have, van der Pijl, Kies, & Deutz, 2015).  575 
Food-drug interactions have been studied in vitro in the case of DPP-IV inhibition (Nongonierma 576 
& FitzGerald, 2013b). It was shown in vitro that Sitagliptin, an antidiabetic drug, and DPP-IV 577 
inhibitory peptides from milk proteins could interact in an additive or synergistic manner to 578 
inhibit DPP-IV (Nongonierma & FitzGerald, 2015c). In vivo studies have also been conducted 579 
where pharmaceutical drugs have been administered together with food protein hydrolysates. 580 
One study has recently evaluated the effect of the concomitant administration of Enaprilat (an 581 
antihypertensive drug) combined with the LTPs (Ile-Pro-Pro and Val-Pro-Pro) or a fish protein 582 
hydrolysate to spontaneous hypertensive rats (SHRs) (Watanabe et al., 2015). A single 583 
administration of the LTPs or the fish protein hydrolysate reduced the antihypertensive effects of 584 
Enaprilat, suggesting that competition during intestinal absorption may occur. However, a 585 
modest additional antihypertensive effect was seen, which was not significant (p > 0.05), when 586 
the LTPs were administered during a long-term (6 weeks) study at day 29 to the Enaprilat group. 587 
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7 Determining the mechanism of action of BAPs 588 
In silico methodologies have been utilised to study structure-activity relationships between BAPs 589 
and various biological activities or organoleptic properties (e.g., bitterness). QSAR approaches 590 
applied to the study of ACE, renin (EC 3.4.23.15) and DPP-IV inhibitory as well as antioxidant, 591 
antimicrobial and bitter peptides have been described in the literature. Peptide structural features 592 
have been determined by QSAR for certain bioactive properties such as ACE, renin and DPP-IV 593 
inhibition (for reviews, see: Iwaniak et al., 2015; Nongonierma & FitzGerald, 2016a). However, 594 
for other biological properties (e.g., antimicrobial, antioxidant and bitterness), while the overall 595 
physicochemical properties of the peptides have been suggested as being important, no clear 596 
favourable peptide sequence has been identified. Interestingly, the importance of hydrophobic 597 
amino acids (Ala, Ile, Leu, Pro, Trp and Val) in BAPs able to inhibit metabolic enzymes has 598 
often been reported in QSAR outcomes (Nongonierma & FitzGerald, 2016a). 599 
To date, it appears that most QSAR analyses have not subsequently employed confirmatory 600 
studies with synthetic peptides to validate the models developed. Not only can QSAR help to 601 
identify novel and potent BAPs, it may also be combined to predict their sensory attributes such 602 
as bitterness to select sequences with enhanced bioactivity and acceptable organoleptic 603 
properties (Pripp & Ardö, 2007; Zhou, Yang, Ren, Wang, & Tian, 2013). In addition, QSAR has 604 
been described as a decision tool to help select potential BAP sequences within large datasets 605 
(Carrasco-Castilla et al., 2012). This may be the case for peptides identified within humans 606 
(Nongonierma & FitzGerald, 2016c) or in peptide sets identified by LC-MS/MS (Majumder & 607 
Wu, 2010; Sagardia et al., 2013). 608 
A number of limitations of QSAR when applied to the study of BAPs have been reported in the 609 
literature. These comprise incorporation of biological activity data obtained using different 610 
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experimental conditions as well as the lack of discrimination of peptides which may act through 611 
different modes of action. In this context, it has been suggested that the mode of inhibition of 612 
ACE should be taken into account in structure activity relationship studies in order to develop 613 
more meaningful models (Jao, Huang, & Hsu, 2012). Recently, it was shown that statistically 614 
significant structure activity relationship models could only be obtained by the inclusion of 615 
competitive DPP-IV inhibitors and IC50 values obtained under the same experimental conditions 616 
(Nongonierma & FitzGerald, 2016c). 617 
Molecular docking has been used to virtually screen peptide sequences with ACE (Norris, Casey, 618 
FitzGerald, Shields, & Mooney, 2012; Pan, Cao, Guo, & Zhao, 2012; Pripp, 2007), DPP-IV 619 
(Nongonierma, Mooney, Shields, & FitzGerald, 2013; Nongonierma, Mooney, Shields, & 620 
FitzGerald, 2014) and xanthine oxidase (XO) (Nongonierma et al., 2013) inhibitory properties. 621 
Molecular docking has also been employed to better understand specific binding of peptides to 622 
enzymes such as ACE (Asoodeh et al., 2014; He, Aluko, & Ju, 2014; Li et al., 2014; Norris et al., 623 
2012; Pan et al., 2012; Pina & Roque, 2009; Zhang et al., 2015), renin (He et al., 2014) and DPP-624 
IV (Velarde-Salcedo et al., 2013). While providing interesting results and allowing, in certain 625 
cases, the identification of enzyme cofactors (e.g., Zn
2+
 for ACE inhibition) (Pina & Roque, 626 
2009) or novel BAPs (Norris et al., 2012), some limitations of molecular docking have been 627 
highlighted. Several molecular docking studies assume peptide binding to the active site of 628 
metabolic enzymes (competitive inhibition). However, this has not always been confirmed 629 
following their in vitro evaluation (Nongonierma et al., 2014). Therefore, it has been suggested 630 
that the mode of inhibition of the peptides should be taken into account in conjunction with 631 
molecular docking analyses. The main difficulty of this approach is that the mode of interaction 632 
of peptides with metabolic enzymes is generally unknown. However, there are a growing number 633 
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of studies which have evaluated the mode of inhibition of metabolic enzymes by peptides using 634 
in vitro protocols based on the Lineweaver and Burke approach. The different modes of ACE 635 
inhibition (competitive, non-competitive and uncompetitive) with dietary peptides have been 636 
reviewed by Jao et al. (2012). Determination of the mode of inhibition of other metabolic 637 
enzymes appears to have been studied to a lesser extent. However, a few examples of peptide 638 
mode of inhibition have been reported for DPP-IV (for review, see: Lacroix & Li-Chan, 2016), 639 
XO (Nongonierma & FitzGerald, 2012b; Nongonierma et al., 2013) and cathepsin B (EC 640 
3.4.22.1) (Lee & Lee, 2000). In general, there is a requirement for more data to be generated to 641 
understand how these BAPs may interact with the enzymes and subsequently inhibit or activate 642 
them. Understanding the mode of interaction between enzymes and peptides is of central 643 
importance in order to determine if these BAPs may act through the same mechanism of action 644 
in comparison to specific pharmaceutical drugs (Pina & Roque, 2009) or whether they may 645 
interact with drugs to further inhibit enzyme activity (Nongonierma & FitzGerald, 2015c). 646 
8 Demonstrating effects of BAPs in humans 647 
Current knowledge on the in vivo bioavailability of BAPs is limited (for reviews, see: Boutrou et 648 
al., 2015; Nongonierma & FitzGerald, 2015b; Nongonierma & FitzGerald, 2016b). However, the 649 
number of nutritional intervention studies reporting on the occurrence of peptides in human 650 
fluids or tissues is increasing (Nongonierma & FitzGerald, 2015a). Examples of studies which 651 
have detected peptides in humans following the ingestion of peptides, food protein hydrolysates 652 
or intact proteins are listed in Table 3. Several peptides with previously reported in vitro ACE 653 
inhibitory, opioid (Boutrou et al., 2013), mineral binding (Meisel et al., 2003) and antithrombic 654 
(Chabance et al., 1995; Chabance et al., 1998) activities have been identified in the 655 
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gastrointestinal contents of humans. Peptides previously identified in the gastrointestinal tract of 656 
humans have been analysed for their potential to act as inhibitors of DPP-IV in vitro. This has 657 
allowed the discovery of two relatively potent DPP-IV inhibitors, Leu-Pro-Val-Pro-Gln and Ile-658 
Pro-Met having IC50 values of 43.8 and 69.5 µM, respectively (Nongonierma & FitzGerald, 659 
2016c). 660 
Identification of peptides, with previously reported in vitro ACE inhibition, anticancer and cell 661 
proliferative effects, in the plasma has also been achieved in a number of human intervention 662 
studies (Table 3). Recently, a very promising study reported for the first time on the detection of 663 
caseinophosphopeptides (CPPs, mineral binding peptides) in the plasma of humans following 664 
ingestion of Parmigiano Reggiano cheese (100 g/day for 7 days) (Caira et al., 2016). Several 665 
CPPs [αs1-CN (f43-52)2P and αs1-CN (f43-50)2P, αs2-CN (f8-12)2P/3P, αs2-CN (f7-12)2P/3P and 666 
αs2-CN (f6-12)3P] as well as non-phosphorylated casein-derived peptides [β-CN (f193-209), β-667 
CN (f194-209) and β-CN (f200-209)] were identified in plasma by LC-MS/MS. The presence of 668 
BAPs in vivo is, however, not sufficient to guarantee that they can exert a positive effect on 669 
human health. In fact, there is still a level of uncertainty as to what concentration of a BAP is 670 
required for biological effects to be seen in humans. 671 
To date, it appears that only a limited number of studies have quantified peptide levels in humans 672 
and in certain instances determined their bioavailability (Table 3). The quantification of BAPs in 673 
human samples have been described using calibrated ELISA methods (Chabance et al., 1995; 674 
Chabance et al., 1998; Meisel et al., 2003) or synthetic peptides in the format of internal or 675 
external (generally isotopically labelled) standards (Foltz et al., 2007; Kaiser et al., 2016; Taga et 676 
al., 2014). Caseinomacropetide (CMP) was quantified (16 and 21 µg mL
-1
) in the plasma of 677 
newborns after ingestion of human milk and bovine milk-based infant formula (Chabance et al., 678 
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1995). Lower levels (0.5-2 and 1.05-10 µg mL
-1
) were reported in adults following milk and 679 
yogurt ingestion (Chabance et al., 1998). Differences between adults and infants were attributed 680 
to the maturity and permeability of their gut and to the feeding pattern (Chabance et al., 1998). 681 
Concentrations of CPPs between 0.2 and 7.10 nmol mL
-1
 were reported in the ileostomy fluid of 682 
humans following ingestion of CPPs or milk, respectively (Meisel et al., 2003). Concentrations 683 
of 17 and 900 µM for the opioid peptide β-casomorphin-7 (β-CN (f60-66)) and the ACE 684 
inhibitory peptide β-CN (f108-113) were reported in the jejunum of humans who had ingested 685 
bovine milk (Boutrou et al., 2013). 686 
Different ACE inhibitory peptides (Table 3) were quantified by LC-MS/MS using the method 687 
developed by van Platerink, Janssen, Horsten, and Haverkamp (2006) in the plasma of adults 688 
following the consumption of an LTP-enriched yoghurt drink (Foltz et al., 2007). The ACE 689 
inhibitory peptides Ile-Trp and Trp-Leu were fed to humans and detected in their plasma at 690 
levels of 2.4 and 29-36 nM, respectively, 30 min following ingestion (Kaiser et al., 2016). In this 691 
study, it was demonstrated for the first time that following ingestion of 50 mg, Ile-Trp could 692 
reduce human ACE activity in plasma by 32  8%. In another study, Val-Tyr, an ACE inhibitory 693 
peptide, was identified in plasma following ingestion of a sardine muscle hydrolysate fraction 694 
(containing 12 mg Val-Tyr), reaching a maximal concentration of 1934 fmol mL
-1 
after 2
 
h 695 
(Matsui et al., 2002). 696 
Lunasin, an anticancer peptide, was detected in the plasma of humans following ingestion of soy 697 
proteins administered in the format of a soy chilli meal (Dia, Torres, De Lumen, Erdman Jr, & 698 
De Mejia, 2009). Concentrations of 50.2-110.6 and 33.5-122.7 ng mL
-1
 were detected in plasma 699 
30 and 60 min following feeding, respectively. It was estimated that these levels would 700 
correspond to an absorption of 4.5% of the amount of lunasin reaching the small intestine. In 701 
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another study, it was hypothesised that Bowman-Birk inhibitor (BBI), a serine protease (8 kDa) 702 
with anticancer properties, may be bioavailable as some of its metabolites (23.6 and 21.6 µg 703 
detected 6 h post ingestion at 36 h apart, respectively) were detected by ELISA in the urine of 704 
humans following soy milk intake (Wan, Lu, Anderson, Ware, & Kennedy, 2000). 705 
Cell proliferative collagen/gelatin-derived peptide bioavailability in humans has been 706 
investigated. Various levels of Hyp containing di- and tripeptides (Table 3) were reported in the 707 
plasma of humans following the ingestion of fish scale or porcine skin gelatin hydrolysates 708 
(Ichikawa et al., 2010; Shigemura et al., 2011; Sugihara et al., 2012). While many of these 709 
studies have allowed the quantification of a limited number of Hyp-containing peptides, a 710 
method employing the utilisation of stable isotope Hyp-containing peptides has recently been 711 
described (Taga et al., 2014). This method has allowed the simultaneous accurate quantification 712 
of free Hyp and 13 Hyp-containing peptides in plasma of humans who had ingested a fish scale 713 
gelatin hydrolysate. It was also shown in this study that the level of free and total Hyp detected 714 
were significantly enhanced (> 1.6 times more) when using the stable isotope internal standard 715 
method. 716 
Overall, the bioavailability of BAPs in humans is generally very low (Table 3). Low 717 
bioavailability has been explained by the fact that peptides may be prone to degradation by 718 
peptidases/proteinases in the gastrointestinal tract and in the serum while low peptide permeation 719 
at the intestinal level has also been described (for reviews, see: Picariello, Mamone, Nitride, 720 
Addeo, & Ferranti, 2013b; Sánchez-Rivera et al., 2014b). Different strategies may be employed 721 
to increase bioavailability of peptides. More particularly, encapsulation of peptides (for review, 722 
see: Mohan, Rajendran, He, Bazinet, & Udenigwe, 2015) may increase their stability to digestive 723 
enzymes (Giroux, Robitaille, & Britten, 2016; Li, Paulson, & Gill, 2015). In addition, 724 
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permeation enhancers may help to increase peptide absorption in the ileum (for reviews, see: 725 
Gleeson, Ryan, & Brayden, 2016; Niu, Conejos-Sánchez, Griffin, O’Driscoll, & Alonso, 2016). 726 
Lipid-based intestinal permeation enhancers (e.g., sodium caprate and the sodium salt of 10-727 
undecylenic acid) were shown to increase the permeation of ACE inhibitory peptides (Ile-Pro-728 
Pro and Leu-Lys-Pro) in Ussing chambers containing rat jejunum and colon (Gleeson, Heade, 729 
Ryan, & Brayden, 2015). 730 
The low bioavailability of peptides raises the question of how much of the peptide(s) should be 731 
ingested to cause an in vivo effect. Utilisation of dose-response approaches to evaluate BAPs in 732 
humans may allow assessment of their in vivo potency. A limited number of human studies have 733 
employed a dose-response approach to understand the level of hydrolysates/BAPs required to 734 
observe a bioactive effect in vivo. Several human intervention studies conducted with the ACE 735 
inhibitory LTPs (Ile-Pro-Pro and Val-Pro-Pro) have demonstrated a dose-response relationship 736 
between their ingestion and SBP reduction. This was the case with a casein hydrolysate, obtained 737 
on casein hydrolysis with an Aspergillus oryzae protease, administered to subjects with mild and 738 
high hypertension at dosages of 1.8, 2.5 and 3.6 mg LTPs for 6 weeks. A reduction in SBP of 739 
5.8, 6.2 and 9.3 mmHg, respectively, was obtained with the three treatments (Mizuno et al., 740 
2005). Similarly, de Leeuw, Van der Zander, Kroon, Rennenberg, and Koning (2009) have 741 
demonstrated a significant reduction (p < 0.05) in SBP in a dose-dependent manner following 742 
LTPs intake (2.3, 4.56 and 9.30 mg/200 g yogurt drink formulated with a casein hydrolysate 743 
containing the LTPs) by mildly hypertensive subjects. A decrease in arterial stiffness was 744 
reported in hypertensive subjects who consumed a Lactobacillus helveticus fermented milk drink 745 
containing 5 or 50 mg/day LTPs for 12 weeks (Jauhiainen et al., 2010). Different doses of a 746 
proprietary casein-derived hydrolysate (InsuVida™) with antidiabetic properties have been 747 
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evaluated in humans (for review, see: Nongonierma & FitzGerald, 2015b). In the study of Jonker 748 
et al. (2011) lower doses of 6 and 12 g hydrolysate were ingested compared to 25-35 g reported 749 
in earlier studies (Manders et al., 2006a; Manders et al., 2005; Manders et al., 2006b; Manders, 750 
Praet, Vikstrom, Saris, & van Loon, 2007; van Loon et al., 2003). Higher insulin secretion and 751 
reduced blood glucose levels were observed in type 2 diabetic subjects only after 12 but not 6 g 752 
hydrolysate intake, showing that certain BAP levels may be required to observe the antidiabetic 753 
properties (Jonker et al., 2011). Matsui et al. (2002) fed humans with three doses (3, 6 and 12 754 
mg) of Val-Tyr (present within a sardine muscle hydrolysate fraction). Val-Tyr could be 755 
absorbed in the blood in a dose-dependent manner. A commercial cod skin gelatin hydrolysate 756 
was fed to humans at three different doses, i.e., 30.8, 153.8 and 384.6 mg per kg body weight 757 
(Shigemura, Kubomura, Sato, & Sato, 2014). Hydrolysate doses > 30.8 mg per kg body weight 758 
were required in order to observe a change in concentration in free Hyp and Hyp-bound peptides 759 
in plasma. In addition, a dose-response pattern was seen between the amount of hydrolysate 760 
ingested and the level of Hyp and Hyp-containing peptides in plasma. It was also shown that at 761 
the highest dose tested (384.6 mg per kg body weight), no limit of absorption of Hyp and Hyp-762 
containing peptides was reached, suggesting that higher doses would yield an increased level in 763 
plasma. 764 
While several studies have identified peptides with in vitro bioactive effects, understanding of 765 
the relevance of these results to in vivo behaviour of peptides is not straightforward. This is 766 
mainly due to major differences in terms of their in vivo bioavailability, stability and transfer 767 
kinetics (Foltz et al., 2010). In order to develop more meaningful in vitro evaluation of peptides, 768 
it has been proposed to reverse the strategy of BAP discovery starting from in vivo knowledge to 769 
inform the release of peptides during in vitro hydrolysis. This may, in turn, improve the 770 
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correlation between in vitro bioassays and in vivo results (Foltz et al., 2010; Nongonierma & 771 
FitzGerald, 2016b). 772 
9 Conclusions 773 
Different targeted approaches have attempted to develop alternative strategies to overcome the 774 
limitations of the conventional approach used in BAP studies. There is a need to develop more 775 
robust scientific hypotheses leading to targeted release of peptides with specific features, 776 
physicochemical properties or predicted bioactivity. To better understand the role of dietary 777 
BAPs in human health, a number of issues still needs to be dealt with, i.e., insufficiently 778 
characterised enzyme preparations, non-standardised protocols (for bioassay assessment, peptide 779 
identification and in vivo evaluation of BAPs), inadequate study of short peptides and lack of 780 
mechanistic studies. A focus on these challenges may allow a “closing of the gap” between in 781 
vitro bioassays, bioavailability and efficacy of BAPs in humans. In addition, knowledge of the 782 
sequence and level of BAPs identified in vivo may constitute the basis for a reversed discovery 783 
approach starting from in vivo bioavailability to inform the generation of BAPs during enzymatic 784 
hydrolysis. A focus on peptides identified within humans is of significant interest as such studies 785 
provide a better understanding of the mechanism of action of BAPs in humans, which is a 786 
requirement from a regulatory point of view. 787 
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Table and figure captions 
 
Table 1. In silico predictive models used to rank dietary proteins based on their potential to act as 
a source of bioactive peptides (BAPs). 
 
Table 2. Examples of studies reporting on short peptide sequence identification within model 
solutions, food protein hydrolysates or plasma samples. 
 
Table 3. Summary of human intervention studies describing the identification and quantification 
of peptides in vivo. 
 
Figure 1. Components employed for the identification and validation of food protein-derived 
bioactive peptides (BAPs). ANN: artificial neural network; DOE: design of experiments; QSAR: 
quantitative structure activity relationship; RSM: response surface methodology. 
 
Figure 2. Summary of the strategies employed to improve the detection and identification of 
short peptides within complex mixtures. CE: capillary electrophoresis; HILIC: hydrophilic 
interaction liquid chromatography; LC: liquid chromatography; MRM: multiple reaction 
monitoring; MS: mass spectrometry; NDA: naphthalene-2,3-dialdehyde; PITC: phenyl 
isothiocyanate; RP: reverse-phase; SIM: selected ion monitoring; SPE: solid phase extraction;; 
UF: ultrafiltration. 
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Table 1 
Parameter estimated Model Unit Reference 
Frequency of occurrence 
of BAP (A) 𝐴 =
𝑎
𝑁
 
none (Dziuba et al., 2003) 
Potential biological 
activity (B) 
𝐵 =
∑ (
𝑎𝑖
𝐸𝐶50,𝑖
)𝑖
𝑁
 
none (Dziuba et al., 2003) 
Frequency of occurrence 
of BAP release (AE) 𝐴𝐸 =
𝑑
𝑁
 
none (Minkiewicz et al., 2011) 
Potency score (Score) 
𝑆𝑐𝑜𝑟𝑒 =
∑ (
1
𝐼𝐶50,𝑖
)𝑖
𝑀𝑊
 
mL mg-1 (Vermeirssen et al., 2004) 
Half maximal inhibitory 
potential (IC50) of a 
protein hydrolysate 
𝐼𝐶50,ℎ𝑦𝑑𝑟𝑜𝑙𝑦𝑠𝑎𝑡𝑒 =
10−6 × 𝑀𝑊
1
𝑎 ×
∑ (
1
𝐼𝐶50,𝑖
)𝑝𝑖=1
 
mg mL
-1
 (Pripp, 2005) 
Potency index (PI) 
PI =
∑ (
1
𝐼𝐶50,𝑖
× 𝑛𝑖,𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑)𝑖
𝑀𝑊
 
μM-1 g-1 (Nongonierma & 
FitzGerald, 2014) 
a: number of bioactive peptide (BAP) sequences found within the protein; A: frequency of BAP occurrence in a protein; AE: frequency 
of BAP occurrence as predicted to be released in silico following digestion of a protein by a specific enzyme activity; ai: number of 
repetitions of peptide i within the protein sequence; B: potential biological activity of the protein; d: number of BAP sequences 
released in silico following digestion of a protein by a specific enzyme activity; IC50,i: half maximal inhibitory concentration of 
peptide i (expressed in M (Vermeirssen et al., 2004) or μM (Nongonierma & FitzGerald, 2014; Pripp, 2005)); IC50,protein: half maximal 
inhibitory concentration of the in silico protein digest; MW: molecular mass of the protein (g mol
-1
); N: number of amino acid 
residues in the protein; ni,corrected: corrected occurrence of peptide i per mol of protein. 
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Table 2 
Sample Peptides identified* Workflow** Bioactivity of 
selected sequences 
Reference 
Human plasma 
collected after oral 
intake of a sardine 
muscle hydrolysate 
Val-Tyr  RP-HPLC fractionation 
 NDA-derivatisation 
 fluorescence detection (excitation and 
emission wavelengths 420 and 490 nm, 
respectively) 
antihypertensive (Matsui et al., 
2002) 
Model solution, gluten 
protein hydrolysate and 
Parmesan cheese 
 
 
10 amino acids, 9 di- and 1 
tripeptide (gluten 
hydrolysate) 
9 dipeptides (parmesan 
cheese) 
 unbound fraction on a C18 column 
(gluten hydrolysate) and 3 kDa permeate 
(cheese water soluble extract) 
 separation on an HILIC column 
 analysis of MS/MS fragments 
n.d. (Schlichtherle-
Cerny et al., 2003) 
Milk protein 
hydrolysate 
71 compounds (amino 
acids and di- to tetra 
peptides) 
 2D LC separation (C18 and HILIC 
columns) 
 accurate mass 
 retention time 
 MS/MS fragmentation 
 synthetic peptides 
antihypertensive (van Platerink et al., 
2008) 
Whey protein 
hydrolysate 
Ile-Val, Leu-Val, Val-Leu, 
Ile-Ile, Leu-Ile, Ile-Leu 
and Leu-Leu 
 MRM of 7 target peptides 
 synthetic peptides 
glucose uptake in 
myotubes and isolated 
skeletal muscles 
(Morifuji et al., 
2009) 
Commercial fish scale 
gelatin hydrolysate 
Hyp containing di- and 
tripeptides 
 MRM of 9 target peptides 
 synthetic peptides 
fibroblast growth (Ichikawa et al., 
2010) 
Atlantic salmon skin 
collagen hydrolysate 
11 di- to pentapeptides  C18 fractionation 
 LC-MS/MS identification 
antihypertensive (Gu et al., 2011a) 
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Commercial fish scale 
gelatin hydrolysate 
Pro-Hyp and Hyp-Gly  SEC fractionation 
 PITC derivatisation 
 MRM 
 Synthetic peptides 
fibroblast growth (Shigemura et al., 
2011) 
Commercial porcine 
skin gelatin hydrolysate 
Pro-Hyp and Hyp-Gly  SEC fractionation 
 PITC derivatisation 
 MRM 
 Synthetic peptides 
fibroblast growth (Sugihara et al., 
2012) 
Atlantic herring by-
products (skin and left 
over material after 
filleting) 
66 di- to hexapeptides  centrifugation and ultrafiltration (10 kDa) 
 nanoflow LC-MS Orbitrap 
 in-house database 
numerous (Pampanin et al., 
2012) 
Commercial and 
experimental L. 
helveticus ATCC 
fermented milks 
Phe-Pro, Val-Pro-Pro, Ile-
Pro-Pro and Leu-Pro-Pro 
 ultrafiltration (10 kDa) 
 pre-column derivatisation with dabsyl 
chloride 
 SIM 
antihypertensive (Eisele et al., 2012) 
Synthetic peptides in a 
mixture and rapeseed 
protein hydrolysate 
numerous  retention time prediction (HILIC, C18 
and CE columns) 
 all possible amino acid combinations 
corresponding to the detected mass. 
 peptide occurrence in rapeseed proteome 
n.d. (Harscoat-Schiavo 
et al., 2012) 
-casein incubated with 
a cell free extract of L. 
helveticus 
12 di- (Xaa-Pro) and 
tripeptides (Xaa-Pro-Pro) 
 ultrafiltration (10 kDa) 
 pre-column derivatisation with dabsyl 
chloride 
 SIM during LC-MS 
 external standards 
antihypertensive (Stressler et al., 
2013) 
Synthetic peptides in a 
mixture and spiked in a 
whey protein 
117 di- and tripeptides (all 
possible combinations of 
Val, Leu and Ile) 
 MRM of 117 target peptides 
 retention time on C18 column 
n.d. (Lahrichi et al., 
2013) 
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hydrolysate  modification of the collision energy 
Gly-Sar and Val-Tyr in 
rat intestinal sections 
Gly-Sar and Val-Tyr  MALDI-IMS 
 phytic acid matrix additive 
antihypertensive (Val-
Tyr) 
(Hong et al., 2013) 
His-Leu-Pro-Leu-Pro 
(β-casein (f134-138)) 
after oral and 
intravenous 
administration and 
breakdown products 
detected in rat plasma 
His-Leu-Pro-Leu-Pro, 
Leu-Pro-Leu-Pro and His-
Leu-Pro-Leu 
 SPE concentration 
 SRM 
 retention time 
 fragmentation profile 
antihypertensive (Sánchez-Rivera et 
al., 2014a) 
Enzymatic hydrolysates 
of Laminaria japonica 
8 Tyr containing di- to 
pentapeptides 
 MRM 
 modification of collision energy 
 synthetic peptides 
antihypertensive (Chen et al., 2015) 
Synthetic peptides in a 
mixture and whey 
protein hydrolysate  
numerous  SPE fractionation 
  accurate mass 
 all possible amino acid combinations 
corresponding to the detected mass. 
 peptide occurrence in milk proteome and 
de novo searches 
 retention time prediction (HILIC column) 
 analysis of MS/MS fragments 
n.d. (Le Maux et al., 
2015a) 
Whey protein 
hydrolysate 
numerous  nanofiltration (300 Da) fractionation  
 accurate mass 
 all possible amino acid combinations 
corresponding to the detected mass. 
 peptide occurrence in milk proteome and 
de novo searches 
 retention time prediction (HILIC and 
C18 columns) 
DPP-IV inhibition (Le Maux et al., 
2015b) 
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 analysis of MS/MS fragments 
Whey and casein 
hydrolysates 
numerous  modification of collision energy 
 modification of transfer time 
 analysis of MS/MS fragments 
n.d. (O’Keeffe & 
FitzGerald, 2015) 
Human plasma (fed 
with Ile-Trp and Trp-
Leu) 
Ile-Trp and Trp-Leu  isotopic labelling 
 MRM 
 modification of collision energy 
 synthetic peptides 
antihypertensive (Kaiser et al., 2016) 
*Peptides identified by their three letter code 
**CE: capillary electrophoresis; C18: octodecyl silane; HILIC: hydrophilic interaction liquid chromatography; LC-MS: liquid chromatography- mass spectrometry; MALDI-IMS: 
matrix-assisted laser desorption ionisation-imaging mass spectrometry; MRM: multiple reaction monitoring; n.d.: not disclosed; NDA: naphthalene-2,3-dialdehyde; PITC: phenyl 
isothiocyanate; RP-HPLC: reverse-phase high pressure liquid chromatography; SEC: size exclusion chromatography; SIM: selected monitoring; SPE: solid phase extraction; SRM: 
pseudoselected reaction monitoring; UF: ultrafiltration; 2D: two dimension. 
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Table 3 
Feed  Protein 
source 
Peptide(s) Location BAP maximal 
concentration 
(Cmax) 
Bioavailability 
(%) 
Bioactivity Reference 
Human milk κ-casein CMP (f106-169) plasma of 
newborns 
16 µg mL
-1
 n.d. antithrombic (Chabance et al., 
1995) 
Bovine milk-based 
infant formula 
κ-casein CMP (f106-169) plasma of 
newborns 
22 µg mL
-1
 n.d. antithrombic  
Bovine milk κ-casein CMP (f106-169) plasma of 
adults 
0.5-2 µg mL
-1
 n.d. antithrombic (Chabance et al., 
1998) 
Bovine yogurt κ-casein CMP (f106-169) plasma of 
adults 
1.05-10 µg mL
-1
 n.d. antithrombic  
CPP preparations 
or bovine milk  
milk n.d. ileostomy 
fluid of 
adults 
0.02 and 7.10 
nmol mg
-1
 
1.8 %  
(120 mg 
CPP/250 g 
milk) 
mineral binding (Meisel et al., 
2003) 
Lactotripeptide 
enriched yoghurt 
drink 
caseins Ala-Trp, Ile-Trp, 
Val-Tyr, Ile-Tyr, 
Phe-Tyr, Leu-
Trp Ile-Pro-Pro 
and Leu-Pro-Pro 
plasma of 
adults 
897-973 pmol L
-1 
(Ile-Pro-Pro) 
152  85 pmol L-1 
(Leu-Pro-Pro) 
n.d. antihypertensive (Foltz et al., 
2007) 
Bovine milk -casein β-casomorphin-7 
(f60-66) 
jejunal 
effluent 
17 µM n.d. opioid (Boutrou et al., 
2013) 
 -casein (f108-113) jejunal 
effluent 
900 µM n.d. ACE inhibition  
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Sardine muscle 
protein hydrolysate 
n.d. Val-Tyr plasma of 
adults 
933 ± 201 to 1934 
± 145 fmol mL
-1 
(for 3
 
and 12 mg 
Val-Tyr intake, 
respectively) 
0.006-0.014% ACE inhibition (Matsui et al., 
2002) 
Commercial fish 
scale gelatin 
hydrolysate 
fish gelatin  Hyp containing 
di- and 
tripeptides 
plasma of 
adults 
60.65 ± 5.74 nmol 
mL
-1
 
n.d. diverse (Ichikawa et al., 
2010) 
Commercial fish 
scale gelatin 
hydrolysate 
fish gelatin Pro-Hyp and 
Hyp-Gly 
plasma of 
adults 
120 nmol mL
-1
 n.d. fibroblast 
growth 
(Shigemura et 
al., 2011) 
Porcine skin gelatin 
hydrolysate 
porcine 
gelatin 
Hyp-Gly plasma of 
adults 
4.2 nmol mL
-1
 n.d. cell 
proliferation 
(Sugihara et al., 
2012) 
Commercial fish 
scale gelatin 
hydrolysate 
fish gelatin Hyp and 13 Hyp 
containing di- 
and tripeptides 
plasma of 
adults 
315 ± 15 (Hyp) 
and 219 ± 4 (total 
Hyp) nmol mL
-1
 
n.d. fibroblast 
growth 
(Taga et al., 
2014) 
Soy protein (50 g 
for 5 days) 
soy Lunasin plasma of 
adults 
50.2-110.6 and 
33.5-122.7 ng mL
-
1
 (after 30 and 60 
min ingestion, 
respectively) 
2.2-7.8%  anticancer (Dia et al., 2009) 
Soy milk (105 and 
175 mg BBI) 
soy BBI metabolites urine 23.6 and 21.6 µg 
(measured 6 h 
after two feeds 36 
h apart) 
< 0.02% of the 
ingested BBI 
anticancer (Wan et al., 
2000) 
Trp-containing 
dipeptides 
n/a 
(synthetic 
peptides) 
Ile-Trp plasma of 
adults 
2.4 nM 0.0027 ± 
0.001% 
ACE inhibition (Kaiser et al., 
2016) 
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  Trp-Leu  29-36 nM 0.021-0.022% ACE inhibition  
ACE: angiotensin converting enzyme; BBI: Bowman-Birk inhibitor; CPP: caseinophosphopeptide; CMP: caseinomacropetide 
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